JP2010525056A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010525056A5 JP2010525056A5 JP2010506133A JP2010506133A JP2010525056A5 JP 2010525056 A5 JP2010525056 A5 JP 2010525056A5 JP 2010506133 A JP2010506133 A JP 2010506133A JP 2010506133 A JP2010506133 A JP 2010506133A JP 2010525056 A5 JP2010525056 A5 JP 2010525056A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkoxy
- pharmaceutically acceptable
- monosubstituted
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- -1 pyridine-4-yl Chemical group 0.000 claims 6
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91331207P | 2007-04-23 | 2007-04-23 | |
| PCT/SE2008/050459 WO2008130320A2 (en) | 2007-04-23 | 2008-04-22 | Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010525056A JP2010525056A (ja) | 2010-07-22 |
| JP2010525056A5 true JP2010525056A5 (enExample) | 2012-06-07 |
Family
ID=39876087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506133A Pending JP2010525056A (ja) | 2007-04-23 | 2008-04-22 | 新規化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8143408B2 (enExample) |
| EP (1) | EP2158198B1 (enExample) |
| JP (1) | JP2010525056A (enExample) |
| KR (1) | KR20100015827A (enExample) |
| CN (1) | CN101687860B (enExample) |
| AR (1) | AR066266A1 (enExample) |
| AU (1) | AU2008241610B2 (enExample) |
| BR (1) | BRPI0810354A2 (enExample) |
| CA (1) | CA2685141A1 (enExample) |
| CL (1) | CL2008001170A1 (enExample) |
| CO (1) | CO6251361A2 (enExample) |
| EC (1) | ECSP099706A (enExample) |
| IL (1) | IL201309A0 (enExample) |
| MX (1) | MX2009011364A (enExample) |
| MY (1) | MY146662A (enExample) |
| NZ (1) | NZ581353A (enExample) |
| PE (1) | PE20090727A1 (enExample) |
| RU (1) | RU2460730C2 (enExample) |
| SA (1) | SA08290245B1 (enExample) |
| TW (1) | TW200848037A (enExample) |
| UY (1) | UY31046A1 (enExample) |
| WO (1) | WO2008130320A2 (enExample) |
| ZA (1) | ZA200907137B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SA08290245B1 (ar) * | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| AR074760A1 (es) * | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| EP3725775A1 (en) | 2009-02-17 | 2020-10-21 | Syntrix Biosystems, Inc. | Pyridine- and pyrimidinecarboxamides as cxcr2 modulators |
| JP2013508456A (ja) * | 2009-10-26 | 2013-03-07 | シグナル ファーマシューティカルズ， エルエルシー | ヘテロアリール化合物の合成方法および精製方法 |
| UA103272C2 (uk) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| US20190192510A1 (en) | 2010-02-01 | 2019-06-27 | Nippon Chemiphar Co., Ltd. | Gpr119 agonist |
| US8779149B2 (en) | 2010-08-23 | 2014-07-15 | Syntrix Biosystems, Inc. | Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators |
| WO2012039657A1 (en) * | 2010-09-22 | 2012-03-29 | Astrazeneca Ab | Novel chromane compound for the treatment of pain disorders |
| CN102408385B (zh) * | 2011-06-20 | 2014-06-18 | 雅本化学股份有限公司 | 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法 |
| CN102408386B (zh) * | 2011-07-27 | 2014-05-07 | 雅本化学股份有限公司 | 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法 |
| CN102603659B (zh) * | 2012-03-01 | 2014-03-26 | 雅本化学股份有限公司 | 1-取代-4-溴-1h-1,2,3-三氮唑-5-羧酸及其制备方法 |
| US9139529B2 (en) * | 2013-01-31 | 2015-09-22 | Vertex Pharmaceuticals Incorporated | Substituted quinoxalines as sodium channel modulators |
| US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
| US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| WO2015119998A1 (en) * | 2014-02-06 | 2015-08-13 | Abbvie, Inc. | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
| KR102412146B1 (ko) | 2015-02-11 | 2022-06-22 | 주식회사 아이엔테라퓨틱스 | 소디움 채널 차단제 |
| EP3375782B1 (en) | 2015-11-13 | 2020-07-29 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blocker |
| CN105541774B (zh) * | 2016-01-13 | 2018-06-15 | 华中师范大学 | 3,4-二氢香豆素类化合物及其制备方法和用途 |
| ES2984497T3 (es) * | 2017-06-30 | 2024-10-29 | Elanco Animal Health Gmbh | Nuevos derivados de azaquinolina |
| TWI835770B (zh) | 2018-01-19 | 2024-03-21 | 美商胞質動力學公司 | 心肌節抑制劑 |
| CA3093189A1 (en) | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| US12187712B2 (en) | 2018-06-26 | 2025-01-07 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| SG11202101632XA (en) | 2018-09-10 | 2021-03-30 | Kaken Pharmaceutical Co Ltd | Novel heteroaromatic amide derivative and medicine containing same |
| WO2020234103A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| EP4301760A1 (en) | 2021-03-04 | 2024-01-10 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8904361D0 (sv) * | 1989-12-22 | 1989-12-22 | Astra Ab | New chroman and thiochroman derivatives |
| WO1994012493A1 (en) * | 1992-11-25 | 1994-06-09 | Sandoz, Ltd. | 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals |
| JPH0827153A (ja) * | 1994-07-12 | 1996-01-30 | Nippon Kayaku Co Ltd | アザクロマン誘導体及びその用途 |
| SE9601110D0 (sv) * | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| GB9713804D0 (en) * | 1997-06-30 | 1997-09-03 | Novo Nordisk As | Particulate polymeric materials and their use |
| JPH1135569A (ja) | 1997-07-22 | 1999-02-09 | Meiji Milk Prod Co Ltd | ポリフェノール化合物及びこれを含有する医薬 |
| SE9702799D0 (sv) * | 1997-07-25 | 1997-07-25 | Astra Ab | New compounds |
| SE9703378D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | New compounds |
| SE9703377D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | New compounds |
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| AR045238A1 (es) * | 2003-08-08 | 2005-10-19 | Vertex Pharma | Compuestos utiles como inhibidores de canales ionicos regulados por voltaje |
| WO2006119451A1 (en) * | 2005-05-04 | 2006-11-09 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyrazines useful as modulators of ion channels |
| JP2009542803A (ja) * | 2006-07-12 | 2009-12-03 | アストラゼネカ・アクチエボラーグ | 鎮痛剤としての３−オキソイソインドリン−１−カルボキサミド誘導体 |
| SA08290245B1 (ar) * | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
-
2008
- 2008-04-21 SA SA8290245A patent/SA08290245B1/ar unknown
- 2008-04-22 RU RU2009138137/04A patent/RU2460730C2/ru not_active IP Right Cessation
- 2008-04-22 NZ NZ581353A patent/NZ581353A/en not_active IP Right Cessation
- 2008-04-22 CA CA002685141A patent/CA2685141A1/en not_active Abandoned
- 2008-04-22 AU AU2008241610A patent/AU2008241610B2/en not_active Ceased
- 2008-04-22 US US12/596,878 patent/US8143408B2/en not_active Expired - Fee Related
- 2008-04-22 MX MX2009011364A patent/MX2009011364A/es active IP Right Grant
- 2008-04-22 CN CN2008800215491A patent/CN101687860B/zh not_active Expired - Fee Related
- 2008-04-22 EP EP08779260A patent/EP2158198B1/en active Active
- 2008-04-22 JP JP2010506133A patent/JP2010525056A/ja active Pending
- 2008-04-22 MY MYPI20094419A patent/MY146662A/en unknown
- 2008-04-22 BR BRPI0810354-2A2A patent/BRPI0810354A2/pt not_active IP Right Cessation
- 2008-04-22 WO PCT/SE2008/050459 patent/WO2008130320A2/en not_active Ceased
- 2008-04-22 KR KR1020097022164A patent/KR20100015827A/ko not_active Withdrawn
- 2008-04-23 AR ARP080101710A patent/AR066266A1/es not_active Application Discontinuation
- 2008-04-23 CL CL2008001170A patent/CL2008001170A1/es unknown
- 2008-04-23 UY UY31046A patent/UY31046A1/es not_active Application Discontinuation
- 2008-04-23 TW TW097114910A patent/TW200848037A/zh unknown
- 2008-04-23 PE PE2008000697A patent/PE20090727A1/es not_active Application Discontinuation
-
2009
- 2009-10-01 IL IL201309A patent/IL201309A0/en unknown
- 2009-10-13 ZA ZA200907137A patent/ZA200907137B/xx unknown
- 2009-10-29 EC EC2009009706A patent/ECSP099706A/es unknown
- 2009-10-29 CO CO09122476A patent/CO6251361A2/es not_active Application Discontinuation
-
2012
- 2012-03-23 US US13/427,981 patent/US20120238579A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010525056A5 (enExample) | ||
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| JP2013542247A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2009514870A5 (enExample) | ||
| JP2013522326A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| JP2015523397A5 (enExample) | ||
| JP2012041349A5 (enExample) | ||
| JP2014521735A5 (enExample) | ||
| JP2013544860A5 (enExample) | ||
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| RU2017105353A (ru) | Соединения | |
| JP2013542261A5 (enExample) | ||
| JP2015503596A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| RU2011153353A (ru) | Кетолидные соединения, обладающие противомикробной активностью | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| TNSN07419A1 (en) | Methods for treating drug resistant cancer |